Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors

Blood (2010) 116 (21): 1292.

https://doi.org/10.1182/blood.V116.21.1292.1292

Published: 2010

Journal Articles

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors

Holbrook E. Kohrt, Brit B. Turnbull, Kartoosh Heydari, Judith A. Shizuru, Ginna G. Laport, David B. Miklos, Laura J. Johnston, Sally Arai, Wen-Kai Weng, Richard T. Hoppe, Philip W. Lavori, Karl G. Blume, Robert S. Negrin, Samuel Strober, Robert Lowsky

Blood (2009) 114 (5): 1099–1109.

https://doi.org/10.1182/blood-2009-03-211441

Published: 2009

Includes: Supplemental data

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Blood (2008) 112 (11): 2162.

https://doi.org/10.1182/blood.V112.11.2162.2162

Published: 2008

Journal Articles

Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies

Jonathan E. Benjamin, MD, PhD, Ginna G. Laport, MD, Laura J. Johnston, MD, Sally Arai, MD, Wen-Kai Weng, MD, PhD, Judith A. Shizuru, MD, PhD, David B. Miklos, MD, PhD, Ruby M. Wong, PhD, Linda V. Elder, Karl G. Blume, MD, Robert S. Negrin, MD, Robert Lowsky, MD

Blood (2008) 112 (11): 4383.

https://doi.org/10.1182/blood.V112.11.4383.4383

Published: 2008

Journal Articles

Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)

Jacob M. Rowe, MD, Zhuoxin Sun, Ph.D, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Peter H. Wiernik, MD, Hillard M Lazarus, MD, Karl G. Blume, MD, Hugo F. Fernandez, MD, Mark R. Litzow, MD, Martin S Tallman

Blood (2008) 112 (11): 49.

https://doi.org/10.1182/blood.V112.11.49.49

Published: 2008

Journal Articles

Long-term remission of Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation–etoposide regimen

Ginna G. Laport, Joseph C. Alvarnas, Joycelynne M. Palmer, David S. Snyder, Marilyn L. Slovak, Athena M. Cherry, Ruby M. Wong, Robert S. Negrin, Karl G. Blume, Stephen J. Forman

Blood (2008) 112 (3): 903–909.

https://doi.org/10.1182/blood-2008-03-143115

Published: 2008

Journal Articles

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Blood (2007) 110 (11): 173.

https://doi.org/10.1182/blood.V110.11.173.173

Published: 2007

Journal Articles

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Blood (2007) 110 (7): 2744–2748.

https://doi.org/10.1182/blood-2007-03-078592

Published: 2007

Journal Articles

Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Frédéric Baron, Jennifer E. Baker, Rainer Storb, Theodore A. Gooley, Brenda M. Sandmaier, Michael B. Maris, David G. Maloney, Shelly Heimfeld, Dmitrij Oparin, Eustacia Zellmer, Jerald P. Radich, F. Carl Grumet, Karl G. Blume, Thomas R. Chauncey, Marie-Térèse Little

Blood (2004) 104 (8): 2254–2262.

https://doi.org/10.1182/blood-2004-04-1506

Published: 2004

Journal Articles

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Steven M. Horwitz, Robert S. Negrin, Karl G. Blume, Sheila Breslin, Monic J. Stuart, Keith E. Stockerl-Goldstein, Laura J. Johnston, Ruby M. Wong, Judith A. Shizuru, Sandra J. Horning

Blood (2004) 103 (3): 777–783.

https://doi.org/10.1182/blood-2003-04-1257

Published: 2004

Journal Articles

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

Wolfgang A. Bethge, Ute Hegenbart, Monic J. Stuart, Barry E. Storer, Michael B. Maris, Mary E. D. Flowers, David G. Maloney, Thomas Chauncey, Benedetto Bruno, Ed Agura, Stephen J. Forman, Karl G. Blume, Dietger Niederwieser, Rainer Storb, Brenda M. Sandmaier

Blood (2004) 103 (3): 790–795.

https://doi.org/10.1182/blood-2003-07-2344

Published: 2004

Journal Articles

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

David G. Maloney, Arthur J. Molina, Firoozeh Sahebi, Keith E. Stockerl-Goldstein, Brenda M. Sandmaier, William Bensinger, Barry Storer, Ute Hegenbart, George Somlo, Thomas Chauncey, Benedetto Bruno, Frederick R. Appelbaum, Karl G. Blume, Stephen J. Forman, Peter McSweeney, Rainer Storb

Blood (2003) 102 (9): 3447–3454.

https://doi.org/10.1182/blood-2002-09-2955

Published: 2003

Journal Articles

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases

Dietger Niederwieser, Michael Maris, Judith A. Shizuru, Effie Petersdorf, Ute Hegenbart, Brenda M. Sandmaier, David G. Maloney, Barry Storer, Thoralf Lange, Thomas Chauncey, Michael Deininger, Wolfram Pönisch, Claudio Anasetti, Ann Woolfrey, Marie-Terese Little, Karl G. Blume, Peter A. McSweeney, Rainer F. Storb

Blood (2003) 101 (4): 1620–1629.

https://doi.org/10.1182/blood-2002-05-1340

Published: 2003

Journal Articles

Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial

Mary E. D. Flowers, Pablo M. Parker, Laura J. Johnston, Alice V. B. Matos, Barry Storer, William I. Bensinger, Rainer Storb, Frederick R. Appelbaum, Stephen J. Forman, Karl G. Blume, Paul J. Martin

Blood (2002) 100 (2): 415–419.

https://doi.org/10.1182/blood-2002-01-0011

Published: 2002

Journal Articles

Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients

Susanne Auffermann-Gretzinger, Izidore S. Lossos, Tamara A. Vayntrub, Wendy Leong, F. Carl Grumet, Karl G. Blume, Keith E. Stockerl-Goldstein, Ronald Levy, Judith A. Shizuru

Blood (2002) 99 (4): 1442–1448.

https://doi.org/10.1182/blood.V99.4.1442

Published: 2002

Journal Articles

In search of the ideal allogeneic inoculum

Karl G. Blume

Blood (2001) 98 (12): 3177.

https://doi.org/10.1182/blood.V98.12.3177a

Published: 2001

Journal Articles

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

Blood (2001) 97 (11): 3390–3400.

https://doi.org/10.1182/blood.V97.11.3390

Published: 2001

Journal Articles

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial

Sandra J. Horning, Robert S. Negrin, Richard T. Hoppe, Saul A. Rosenberg, Nelson J. Chao, Gwynn D. Long, B. William Brown, Karl G. Blume

Blood (2001) 97 (2): 404–409.

https://doi.org/10.1182/blood.V97.2.404

Published: 2001

Journal Articles

Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma—A Feasibility Study

Volker L. Reichardt, Craig Y. Okada, Arcangelo Liso, Claudia J. Benike, Keith E. Stockerl-Goldstein, Edgar G. Engleman, Karl G. Blume, Ronald Levy

Blood (1999) 93 (7): 2411–2419.

https://doi.org/10.1182/blood.V93.7.2411

Published: 1999

Journal Articles

Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group

Blood (1997) 90 (10): 3844–3852.

https://doi.org/10.1182/blood.V90.10.3844

Published: 1997

NARROW

Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies

Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)

Long-term remission of Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation–etoposide regimen

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial

Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients

In search of the ideal allogeneic inoculum

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial

Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma—A Feasibility Study

Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only